Exploring Niclosamide: CAS 50-65-7 Overview and Uses
Exploring Niclosamide: CAS 50-65-7 Overview and Uses reveals that Niclosamide, a pharmaceutical compound with the CAS number 50-65-7, is primarily recognized as an antihelminthic agent traditionally used to treat tapeworm infections. Originally developed over six decades ago, this compound has gained attention not only for its antiparasitic properties but also for its potential application against various types of cancers and viral infections, particularly in the context of recent global health challenges.
Want more information on Niclosamide CAS 50-65-7(it,in,vi)? Feel free to contact us.
Niclosamide was first introduced to the market in the late 1960s. Initially, it served as a treatment for intestinal cestode infections in humans. The compound's mechanism of action involves the inhibition of ATP synthesis in parasitic organisms, leading to their eventual death. As research progressed, scientists began exploring other possible applications for Niclosamide CAS 50-65-7, particularly its effects on non-parasitic diseases. Studies have shown that it exhibits a broad range of biological activities, including antiproliferative and anti-inflammatory effects, which have intrigued the scientific community.
One notable factor that spurred research into alternate uses of Niclosamide is its low toxicity profile in humans. This characteristic makes it a candidate for repurposing in the treatment of conditions beyond parasitic infections. For instance, researchers have been exploring its efficacy in cancer therapy, particularly in inhibiting the growth of various cancer cell lines and enhancing the effectiveness of other chemotherapeutic agents. Furthermore, its antiviral potential has been investigated, especially concerning viral pathogens such as Zika and more recently SARS-CoV-2, the virus responsible for COVID-19. These studies have been crucial in understanding how a long-established drug can be adapted to tackle contemporary health challenges.
Contact us to discuss your requirements of Veterinary APIs. Our experienced sales team can help you identify the options that best suit your needs.
The significance of Niclosamide CAS 50-65-7 extends into the public health domain as well. The increasing resistance of pathogens to current treatment options has prompted healthcare professionals to look for alternative solutions. Additionally, the need for accessible and effective treatments has never been more apparent, given the global pandemic and the rising number of cancer cases. By repurposing Niclosamide, researchers aim to broaden the therapeutic arsenal available to treat these complex diseases, especially in underserved populations where access to newer, more expensive medications may be limited.
Recent clinical trials are providing further data on the efficacy and safety of Niclosamide in the context of oncology and virology, with promising preliminary results. If successful, the findings could lead to a resurgence in the use of this older compound, positioning it as a critical player in the future of treatment paradigms. The discussions surrounding Niclosamide’s multifaceted potential represent a larger trend in medicine: leveraging existing drugs to address untapped therapeutic areas. This not only helps speed up the drug development process but also poses a cost-effective solution in managing treatment for various diseases.
In conclusion, Niclosamide, epitomized by its CAS number 50-65-7, stands at the intersection of historical pharmaceutical significance and modern medical innovation. As research continues to unfold, the exploration of its uses beyond its initial application holds promise for enhancing therapeutic strategies in combating a variety of health threats. The journey of Niclosamide is a testament to the adaptability of medical science and the potential of older drugs to provide new hope in an era of emerging global health crises.
If you are looking for more details, kindly visit Acewell.